Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.

Kensei Yamaguchi,Satoru Iwasa,Motohiro Hirao,Takashi Oshima,Kazuaki Harada,Yasuyoshi Sato,Akihito Kawazoe,Kan Yonemori,Kazuhiro Nishikawa,Nozomu Machida,Yoshito Komatsu,Takuya Suzuki,Shiori Okumura,Reiko Nagai,Takao Takase,Kohei Shitara

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.

2021

Kensei Yamaguchi
Satoru Iwasa
Motohiro Hirao
Takashi Oshima
Kazuaki Harada
Yasuyoshi Sato
Akihito Kawazoe
Kan Yonemori
Kazuhiro Nishikawa
Nozomu Machida
Yoshito Komatsu
Takuya Suzuki
Shiori Okumura
Reiko Nagai
Takao Takase
Kohei Shitara

4025Background: Eribulin has proven efficacy in previously treated metastatic breast cancer and liposarcoma. E7389-LF is a new formulation that uses liposomes to encapsulate eribulin, which is anti...

Keywords:

Medicine
Internal medicine
Cohort
advanced gastric cancer
Oncology
Liposome
Metastatic breast cancer
Liposarcoma
Eribulin
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations